ReviewTumori2024
Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting.
Review in Tumori, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.Tumori · 2026Article
- Clonal relationship in a rare pulmonary mixed tumor: shared ALK fusion in atypical carcinoid and adenocarcinoma-a case report.Translational lung cancer research · 2026Article
- "Variant matters": the impact of ALK fusion subtypes on progression and response in non-small-cell lung cancer-data from clinical practice from Polish centers.Translational lung cancer research · 2026Article
- High-accuracy prediction of mutations in nine genes in lung adenocarcinoma via two-stage multi-instance learning on large-scale whole-slide images.Diagnostic pathology · 2025Article
- Article
- The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication.Translational cancer research · 2025Article
- [Molecular pathology of lung adenocarcinomas, EGFR T790M resistance mutation study].Magyar onkologia · 2024Article
- Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Landscape of targeted therapies for lung squamous cell carcinoma.Frontiers in oncology · 2024Review
- Exploring the Profiles of ROS1 Tyrosine Kinase: A Structural Analysis of G2032R and D2033N Mutations.International journal of applied & basic medical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.